Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZTEC: SABR + Atezolizumab in TNBC
NCT03464942Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Aug 2018
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple negative breast cancer (TNBC), sponsored by Peter MacCallum Cancer Centre. Started Aug 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03464942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464942.